Business
Halberd Corporation’s Research Breakthrough - Qualitative & Quantitative Measurement of Covid-19 Antigens and/or Antibodies
Halberd Corporation’s Research Breakthrough - Qualitative & Quantitative Measurement of Covid-19 Antigens and/or Antibodies.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / January 25, 2021 / Halberd Corp. (OTC PINK:HALB) research produces qualitative and quantitative diagnostic methodology to detect the presence of the SARS-COV-2 antigen/antibody in a bodily fluid test sample. This technology could be used to quantify the antigen/antibody levels present and degree of infection, degree of protection and susceptibility to infection. This is in contrast to many widely used diagnostic tests which provide only a positive or negative result for the presence of the antigen/antibody.Dr. Patricio Reyes, Halberd Corporation's Chief Technical Officer, stated, "As disease variants become prevalent and as population infection levels rise, the need for more definitive testing information is imperative. Our technology could serve as a powerful clinical tool to help determine the presence and severity of COVID-19 and related diseases, monitor response to therapy, and allow the development of more effective treatment. It could also have worldwide economic impact because it could identify affected individuals who may need prompt or aggressive treatment that could shorten hospital stays and prevent long term complications as well as pinpoint infected patients who may not require costly therapeutic intervention or vaccination.Dr. Felder, a prominent consultant to Halberd Corporation, observed, "This should have a profound effect on future research. The efficacy of treatment depends upon knowing not just that a given patient had certain results following an infection, but medical personnel must be able to identify the degree of infection and the number of antibodies present by the patient's immune response. These details are indispensable as a therapeutic tool."William A. Hartman, Chairman, President & CEO, added, "This could be a real breakthrough, allowing medical personnel to tailor the treatment to the specific needs of the patient! Being able to determine the level of infection and/or the level of antibodies, and not just their presence, could allow physicians to provide the exact level of care each patient needs, thereby conserving scarce resources for those who need it most. It could also help identify when a patient would need a boost to their immunity through re-vaccination or other treatment. It could also test the efficacy of a treatment or o...